Roche taps local expertise for hep C drug in China

Roche taps local expertise for hep C drug in China

Roche has enlisted the aid of Chinese-American biotech company Ascletis to help bring its hepatitis C virus (HCV) therapy danoprevir to the market in China. Under the terms of the deal, Ascletis will have responsibility for funding the development

No tags for this post.
39
Like
Save

Comments

Comments are disabled for this post.